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Kv10.1 (Eag1), member of the Kv10 family of voltage-gated potassium channels, is preferentially expressed in
adult brain. The aim of the present study was to unravel the functional role of Kv10.1 in the brain by generating
knockout mice, where the voltage sensor and pore region of Kv10.1 were removed to render non-functional pro-
teins through deletion of exon 7 of the KCNH1 gene using the ‘3 Lox P strategy’. Kv10.1-deficient mice show no
obvious alterations during embryogenesis and develop normally to adulthood; cortex, hippocampus and cere-
bellum appear anatomically normal. Other tests, including general health screen, sensorimotor functioning and
gating, anxiety, social behaviour, learning and memory did not show any functional aberrations in Kv10.1 null
mice. Kv10.1 null mice display mild hyperactivity and longer-lasting haloperidol-induced catalepsy, but there
was no difference between genotypes in amphetamine sensitization and withdrawal, reactivity to apomorphine
and haloperidol in the prepulse inhibition tests or to antidepressants in the haloperidol-induced catalepsy.
Furthermore, electrical properties of Kv10.1 in cerebellar Purkinje cells did not show any difference between
genotypes. Bearing in mind that Kv10.1 is overexpressed in over 70% of all human tumours and that its inhib-
ition leads to a reduced tumour cell proliferation, the fact that deletion of Kv10.1 does not show a marked pheno-
type is a prerequisite for utilizing Kv10.1 blocking and/or reduction techniques, such as siRNA, to treat cancer.
INTRODUCTION
The Drosophila ether-a`-go-go (eag) gene is the founding
member of an evolutionarily conserved superfamily of
voltage-gated potassium channels with homology to cyclic
nucleotide-gated channels (1–3). Mutations in eag in adult
flies cause ether-induced shaking (4,5) and memory formation
defects (6). The effects of eag mutations in Drosophila appear
not entirely dependent on ion permeation, but rather on inter-
action with MAPK (7). One of the hallmark features of
hKv10.1 channels is their sensitivity to intracellular Ca
2+
mediated by calmodulin (CaM) (8), through the Ca2+/CaM
binding domain (9–11). Mutation in this domain reduced in-
hibition of the functional channel by Ca2+/CaM (10,11).
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Mammalian genomes contain at least seven orthologs of the
eag subfamily. Two members, Kv10.1 (Eag1) (12,13) and
Kv10.2 (Eag2) (8,14), share about 70% identity in amino
acid sequence (8). In adult mammals, the expression of
hKv10.1 channels is restricted to the nervous system (13);
however, hKv10.1 is found in over 70% of all human
tumour tissues (15–23) making Kv10.1 an attractive target
for the development of diagnostic and therapeutic tools in on-
cology (24). Their function in brain and during tumour devel-
opment and progression still needs to be elucidated.
In brains of adult rats, Kv10.1 shows the highest mRNA ex-
pression in olfactory bulb, cerebral cortex, hippocampus and
cerebellum (8,25); mRNA expression is highly correlated
with detection of Kv10.1 protein (26). Given that Kv10.1
appears largely neuron specific and localized at synapses
(27), Kv10.1 signalling may regulate activity-dependent
changes in neuronal function such as the excitability and
firing dynamics of Purkinje cells (PCs) that expressed
Kv10.1, but not its paralogue Kv10.2 (8,25,28).
Although a correlation of Kv10.1 to neurological disorder
has not been described yet, an evidence for a schizophrenia-
susceptibility locus in Kv10.1 region was found in a genome-
wide genetic linkage analysis (29). These results are consistent
with first immunohistochemical analysis of human brain sec-
tions that showed lower protein expression of Kv10.1 in the
frontal cortex and hippocampus of patients suffering from
schizophrenia in comparison to non-schizophrenic subjects
(S. Martin, personal communication).
Potassium channels, including Kv10.1, have also been
implicated in antidepressant action (30–32). Imipramine
blocks Kv10.1 channels by occluding the permeation
pathway and possibly affects the cell cycle (32); this offers a
potential mechanism by which imipramine causes a significant
reduction in melanoma cells proliferation (33).
Therefore, the aim of this study was to investigate the func-
tional role of Kv10.1 in brain in vivo using behavioural, mor-
phological and electrophysiological characterization of
Kv10.1-deficient mice generated by the ‘3 Lox P strategy’.
In these mice the voltage sensor and pore region of Kv10.1
were removed to render non-funtional proteins. To this aim,
general health screening and behaviour studies were per-
formed, including sensorimotor functioning and gating,
anxiety, social behaviour, learning and memory, AMPH sensi-
tization, haloperidol-induced catalepsy and its modification by
antidepressants as well as disruption of prepulse inhibition by
apomorphine and its reversal by haloperidol. We report that
Kv10.1-deficient mice display mild hyperactivity and longer
lasting haloperidol-induced catalepsy in comparison to con-
trols, but otherwise normal behaviour, and no obvious histo-
logical changes or differences in electrophysiological
responses in the cerebellum.
RESULTS
Generation and characterization of Kv10.1-deficient mice
To determine the physiological role of Kv10.1 in vivo, we gen-
erated Kv10.1-deficient mice by homologous recombination in
embryonic stem (ES) cells to disrupt part of the Kv10.1 gene
(Fig. 1A). To avoid the possibility of early lethality of total
Kv10.1-deficient mice, the ‘3 Lox P strategy’ was used to gen-
erate total and conditional knockout mice. We screened a
mouse genomic library in lambda phages (Stratagene) to
isolate a fragment of mouse genomic DNA encompassing
the entire Exon 7, which encodes amino acid residues 344–
388 of the Kv10.1 peptide, that was chosen as the targeting
region to produce non-functional Kv10.1 proteins. Exon 7
encodes the voltage sensor and pore-lining regions of
Kv10.1; with this deletion, even in the case of unknown alter-
native splicing or transcription start sites, the resulting protein
would lack voltage dependence and ion permeability. A re-
placement vector was designed to introduce three tandem
repeats of Lox P sites flanking both ends of Exon 7 and a neo-
mycin resistance (Neo) selection cassette. ES cells were trans-
fected and selected for homologous recombination through
positive (Neo) and negative (HSV-tk) double selection
(Fig. 1A). Recombinant ES clones were selected by Southern
Blot analysis (Fig. 1B), injected into blastocysts and trans-
ferred into a pseudo-pregnant foster mother. Mice heterozy-
gous for the lox P-flanked Kv10.1 locus and for the Neo
cassette Kv10.1
NeoLoxP were obtained after breeding the result-
ing male chimeras with C57BL6/N females. To get in vivo
partial (floxed allele) and/or total excision (null allele) of
Lox P-flanked sequence in the targeted loci, heterozygous
mice were crossed with EllaCre transgenic mice that provide
an early expression of Cre recombinase during embryogenesis.
The absence of both Kv10.1 mRNA and Kv10.1 protein in the
knockout mice was confirmed by real time RT-PCR and
western blot analyses [previously described (26)]. As shown
in Figure 1C, no Kv10.1 product was amplified from
Kv10.1
2/2 brain, whereas Kv10.1
+/2 mice expressed approxi-
mately half of the amount of Kv10.1 message found in the
brain of Kv10.1
+/+ mice. Western blot analysis using proteins
isolated from total brain of Kv10.1
+/+ and of Kv10.1
2/2 mice
did not detect Kv10.1 in Kv10.1
2/2 mice (Fig. 1D). Important-
ly, we did not detect an increase in the expression of the
closely related potassium channel Kv10.2 at the RNA level
by real time RT-PCR in response to the absence of Kv10.1 ex-
pression (Fig. 1E). Possible genetic compensation was
assessed by microarray analysis on hippocampal cDNA of
Kv10.1
+/+ and Kv10.1
2/2 (Supplementary Material,
Table S1); except for the targeted gene itself, no significant
differences were observed between the samples.
Kv10.1
2/2 mice are viable and fertile and display
a morphologically normal brain
Genotyping of litters from intercrosses of F1 Kv10.1
+/2
revealed that Kv10.1
2/2 mice appeared in Mendelian ratios.
From 200 mice, 25% were Kv10.1
+/+, 49% were Kv10.1
+/2
and 26% were Kv10.1
2/2, indicating no embryonic lethality
of Kv10.1
2/2. Breeding studies also indicate that Kv10.1
2/2
mice could interbreed, proving that they are fertile (Data not
shown).
Detailed histological analysis of Nissl-stained brain sections
and immunohistochemical analysis of adjacent sections with
antibodies directed against neuronal markers, including the
calcium-binding proteins calbindin and calretinin and neuronal
nuclei (NeuN), did not reveal any significant differences of
morphology between Kv10.1
+/+ and Kv10.1
2/2. The structure
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and layering of the cortex shown by Nissl and NeuN staining
were indistinguishable for both genotypes (Fig. 2A–D), and
no evident difference could be detected in the organization
of the hippocampus (Fig. 2E and F). Nissl, calbindin and cal-
retinin staining indicate that PCs, molecular layer dendrites
and axonal fibres in the cerebellum appeared unchanged in
both genotypes (Fig. 2G–L). Electron microscopy analysis
of the parallel fibre to PC dendrite synapses in the molecular
layer also revealed no obvious differences (Fig. 2M and N).
Electrical properties of Kv10.1 in cerebellar PCs
Voltage-gated potassium channels play various important
roles in the central nervous system such as modulation of
the resting potential, control of excitability and repolarization
of the membrane after an action potential (34). Kv10.1
activates close to the resting potential (12). Therefore, we
decided to investigate its implication in determining the
resting potential and excitability of cerebellar PCs that
express Kv10.1 (26). PCs under whole-cell patch clamp in
current clamp mode were held close to 260 mV by current in-
jection. On further injection of a depolarizing current, cells
from both genotypes showed tonic firing of action potentials.
Figure 3A shows a typical recording from a Kv10.1
+/+ (top)
and Kv10.1
2/2 (middle) cell and a representative action po-
tential recorded in a Kv10.1
+/+ (bottom left) and Kv10.1
2/2
(bottom right) cell. Without current injection, Vmem was
–63.90+ 3.33 mV (n ¼ 8) in Kv10.1+/+ cells versus
–54.78+ 2.31 mV (n ¼ 8) in Kv10.1-deficient cells.
However, because the potential measured by whole-cell
patch clamp is influenced by the quality of the preparation
and the damage to the cell caused by the patch pipette, these
Figure 1. Generation and expression analysis of Kv10.1-deficient mice. (A) Schematic representation of the Kv10.1
+/+ locus, the targeting construct and the
mutated alleles. Kv10.1
neoLoxP were bred with EllaCre transgenic mice to produce in vivo floxed allele and/or null allele due to an early expression of Cre re-
combinase during mouse embryo development. The probe for Southern blot analysis and primers for genotyping are indicated. (B) Southern blot analysis of
Kv10.1-ES cells (HindIII digested) is shown. Bands corresponding to the different alleles are indicated (wild-type allele: 7.2 Kb Kv10.1; recombinant allele:
2.25 Kb Kv10.1). (C) Real time RT-PCR on cDNA was obtained from total brain RNA in Kv10.1
+/+, Kv10.1
+/2 and Kv10.1
2/2 mouse. The results indicate
a compete deletion of Kv10.1 on Kv10.1
2/2 animals. (D) Western blot using a polyclonal anti-Kv10.1 antibody did not detect specific signals in brain Kv10.1
2/2
mice. The filled arrowhead marks the expected position for Kv10.1; non-specific bands are marked by an asterisk. Open arrowhead shows a-tubulin used as a
control. (E) Real time RT-PCR on cDNA obtain from cortex, hippocampus, brain stem, striatum, thalamus, hypothalamus, hypophysis, olfactory bulb, cerebel-
lum and spinal cord from Kv10.1
+/+ and Kv10.1
2/2 mice. Kv10.2 expression is not regulated due to the absence of Kv10.1 in Kv10.1
2/2 mice.
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results need to be interpreted carefully. To calculate the input
resistance, we injected square current pulses (2100 to
+100 pA in steps of 20 pA) into the soma and recorded the
resulting changes in membrane voltage. The obtained
current–voltage (I–V) relationship for hyperpolarizing
current injection is close to linear with the slope representing
the membrane resistance (35). Neither the obtained values for
Vmem nor the slope of the fit were significantly different
between Kv10.1
+/+ (solid circles) and Kv10.1
2/2 cells
(open circles) (Fig. 3B).
Next, we examined whether injection of depolarizing
voltage pulses leads to changes in the firing frequencies of
PCs. Cells were held close to 260 mV in current clamp
mode, and square current pulses ranging from 2100 to
+100 pA in steps of 10 pA and from +100 to +1000 pA in
steps of 50 pA were injected. The minimal current injection
to elicit an action potential was not significantly different in
Kv10.1
+/+ and Kv10.1
2/2 cells (104.0+ 38.68pA, n ¼ 5
and 61.67+ 21.51, n ¼ 6). Spikes were detected as a local
maximum, and the resulting spike frequencies were plotted
against the injected current (Fig. 3C). Kv10.1
2/2 neurons
showed slightly, but not significantly, increased evoked
firing frequencies in comparison to Kv10.1
+/+ cells on injec-
tion of currents , 100 pA. To evaluate whether Kv10.1 is
involved in shaping the action potential, the first 10 action
potentials occurring after breaking the membrane were aver-
aged and analysed for each cell (Fig. 3D). The comparison
of the after hyperpolarization (i), full width at half
maximum (ii), overshoot (iii) and threshold (iv) of the action
potential revealed no significant differences between
Kv10.1
2/2 neurons and Kv10.1
+/+ cells. Equivalent results
were obtained when comparing the electrophysiological
Figure 2. Normal morphology of the brain of Kv10.1
2/2 mice. Nissl staining of comparable sagittal brain sections from Kv10.1
+/+ (A) and Kv10.1
2/2
(B) (5 mm, paraffin). Representative images of sagital brain sections at 10× magnification stain with NeuN of the neocortex and hippocampus (Kv10.1+/+:
C and E; Kv10.1
2/2: D and F). Representative images of cerebellum stained with NeuN (Kv10.1
+/+: G; Kv10.1
2/2: H), calbindin (Kv10.1
+/+: I;
Kv10.1
2/2: J) and calretinin (Kv10.1
+/+: K; Kv10.1
2/2: L). Scale bar 200 mm. Morphology of the parallel fibre to PC dendrite synapses in the molecular
layer appears normal in Kv10.1
+/+ (M) and Kv10.1
2/2 (N) using electron microscopy. BG, Bergmann glia. Scale bar, 500 nm.
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properties of hippocampal granule cells from Kv10.12/2
(n ¼ 8) and Kv10.1+/+ (n ¼ 4) mice (Data not shown).
Behavioural tests
Mild hyperactivity in Kv10.1-deficient mice
To document general health, we determined 16 parameters, in-
cluding, e.g. body weight, coat condition, motoric abilities,
reflexes, reactivity to handling, spontaneous behaviours and
olfaction (for the full list of tests and results, see Table 1);
we found no differences between genotypes in any of these
parameters.
There was a non-significant tendency towards a main effect
of genotype on spontaneous locomotor activity during a
60 min test session [F(1,29) ¼ 3.51, P , 0.07] and a signifi-
cant genotype × within session period interaction
[F(11,23) ¼ 2.33, P , 0.01]. Kv10.12/2 mice were more
active during all 5 min periods except for the first 15 min
(post hoc tests, minimum P , 0.03). This difference tended
to increase as testing continued (Fig. 4A). There was no differ-
ence between genotypes in coordination and motor learning in
the rotarod test [Fig. 4B; F(1,29) ¼ 0.005, n.s.]. Both geno-
types improved their performance on consecutive tests
[F(2,29) ¼ 22.51, P, 0.0001].
Short-term effects of amphetamine (AMPH) withdrawal
in Kv10.1
2/2 mice
Amphetamine (AMPH) withdrawal had no impact on anxiety
(Table 2, light-dark box) or social behaviour (Table 3), but
Figure 3. Electrophysiological properties of cerebellar PCs of Kv10.1
+/+ and Kv10.1
2/2 mice. (A) top, representative recordings of a spike train in response to a
superthreshold current injection in a PC from a Kv10.1
+/+ mouse. Centre, same from a Kv10.1
2/2 mouse. Bottom, representative action potentials recorded in
Kv10.1
+/+ (left) and Kv10.1
2/2 (right) cells. (B) Membrane voltage in response to current injections ranging from 2100 to +100 pA in steps of 20 pA as
measured in the cell bodies of Kv10.1
+/+ (solid circles) and Kv10.1
2/2 (open circles) PCs. (C) Firing frequencies of Kv10.1
+/+ (solid circles) and
Kv10.1
2/2 (open circles) PCs in response to somatic current injection ranging from 2100 to +100 pA in 10 pA steps and from +100 to +1000 pA in
50 pA increments. (D) Action potential properties of Kv10.1
+/+ (solid circles) and Kv10.1
2/2 (open circles) PCs. The first 10 spontaneously occurring
action potentials were averaged in a given cell and after hyperpolarization (i), full width at half maximum (ii), overshoot (iii) and threshold (iv) were compared.
Table 1. General health screening
Kv10.1
+/+ Kv10.1
2/2
General health
Body weight (g) 21.71+0.27 22.34+0.34
Poor coat condition (%) 0 0
Bald patches (%) 0 0
Missing whiskers (%) 0 0
Piloerection (%) 0 0
Physical abnormalities (%) 0 0
Motoric abilities
Trunk curl (%) 69 73
Forepaw reaching (%) 100 100
Inverted screen (s) 60 60
Reflexes (% of mice normal)
Ear twitch (%) 100 100
Whisker twitch (%) 100 100
Reactivity
To handling (three-point scale) 0.94 1
Empty cage behaviour (3 min test)
Freezing (%) 0 0
Wild running (%) 0 0
Grooming (s) 6.04+0.73 8.92+1.66
Grooming (events) 3.06+0.49 3.6+0.65
Olfaction (3 min test; diluted oil drop on the wall)
Sniffing time (s) 6.72+0.74 5.1+0.94
Number of sniffs 5.63+0.69 4.8+0.49
Latency to first sniff (s) 38.74+7.84 31.53+7.48
There were no significant between genotype differences in tests measuring
animals’ general health and sensorimotor abilities (for details, see Materials
and Methods). Data are shown as mean+SEM; n ¼ 15–16 per group.
There was no between groups difference in any of the above parameters.
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decreased circadian locomotor activity [Fig. 5A; F(1,27) ¼
8.85, P, 0.01] and 23 h sucrose solution consumption
[Fig. 5B; F(1,27) ¼ 15.74, P , 0.001] in both genotypes. No
effects of genotype were found in those tests except a signifi-
cant group × circadian phase interaction [F(1,3592) ¼ 26.90,
P, 0.0001] with Kv10.1
2/2 mice being more active than
Kv10.1
+/+ during the night (post hoc test P , 0.0001), but
not the day phase.
Long-term effects of AMPH withdrawal in Kv10.1
2/2 mice
Starting 3 weeks after AMPH withdrawal, circadian activity,
23 h sucrose solution consumption (Fig. 5D), anxiety
(Table 2, the elevated plus maze test and hyponeophagia),
learning and memory (Table 4, Y maze spatial novelty test,
T maze spontaneous alternations test and fear conditioning)
and sensorimotor gating (Table 5) were measured. No
between genotype differences and no interactions with
AMPH sensitization status were found in those tests except
for circadian activity. Equivalent increases in activity were
found in animals exposed to the drug irrespectively of geno-
type [Fig. 5C; F(1,27) ¼ 11.70, P, 0.01], and a significant
genotype × circadian phase interaction was found
[F(1,3592) ¼ 6.82, P , 0.01] with Kv10.12/2 mice highly
significantly more active than Kv10.1
+/+ during the night
(post hoc, P, 0.0001), but only slightly during the day
phase (P ¼ 0.05).
Figure 4. Increased spontaneous activity (A) and normal motor coordination and motor learning in the rotarod test (B) in Kv10.1
2/2 mice (for details,
see Materials and Methods). Data are shown as mean + SEM; n ¼ 15–16 per group. ∗ P , 0.05 versus Kv10.1+/+.
Table 2. Anxiety
Test/parameter Kv10.1
+/+ Kv10.1
2/2 Kv10.1
+/+AMPH Kv10.1
2/2 AMPH
Light/dark box Within 6 days after AMPH withdrawal
Transitions 18+2.36 25+1.58 18.88+1.23 19.14+1.37
Latency to enter the dark side (s) 8.33+2.09 9.71+2.53 17.07+5.70 12.87+3.59
Distance travelled (cm) 931.35+105.52 1012.06+83.69 1035.11+100.36 1000.43+118.09
Time in dark zone (s) 434.18+18.78 396.08+23.99 416.09+27.38 448.86+11.80
Elevated plus maze 3 weeks after AMPH withdrawal
Open arms entries (%) 24.89+3.58 24.66+4.24 20.33+3.12 21.13+3.39
Time in open arms (%) 5.44+1.10 7.03+1.68 7.31+2.26 4.63+1.56
Closed arms entries 11.50+2.01 12+2.17 11.50+1.52 7.71+1.44
Hyponeophagia 3 weeks after AMPH withdrawal
Latency to eat (s) 202.13+47.52 288.88+45.12 211.25+49.93 253.86+40.44
Lack of genotype and AMPH withdrawal effects on anxiety (for details, see Materials and Methods). Data are shown as mean+SEM; n ¼ 7–8 per group.
Table 3. Effects on sociability and social novelty after AMPH treatment
Test/parameter Kv10.1
+/+ Kv10.1
2/2 Kv10.1
+/+AMPH Kv10.1
2/2 AMPH
Sociability Within 6 days after AMPH withdrawal
Proximal contact (s) Social side 113.06+18.38 97.23+15.97 100.80+18.12 134.99+22.08
Empty side 65.54+12.09 74.71+14.10 72.35+21.36 56.61+17.82
Social novelty Within 6 days after AMPH withdrawal
Proximal contact (s) Novel 72.30+13.64 69.09+11.68 72.50+8.27 81.80+12.90
Familiar 51.98+5.52 45.54+5.88 61.86+8.23 78.46+13.64
Lack of genotype and AMPH withdrawal effects on sociability and social novelty preference measured in the three chamber apparatus (for details, see Materials
and Methods). Data are shown as mean+SEM; n ¼ 7–8 per group.
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AMPH challenge
There were no significant differences in activity due to geno-
type or AMPH sensitization status during an initial 60 min ha-
bituation session [F(1,27) ¼ 0.00, n.s. and F(1,27) ¼ 1.79,
n.s., respectively] or during the 60 min after vehicle injection
[F(1,27) ¼ 0.48, n.s. and F(1,27) ¼ 0.33, n.s., respectively].
AMPH injection (1 mg/kg) increased activity to a higher
degree in AMPH-sensitized animals [Fig. 6, F(1,27) ¼
33.02, P , 0.0001] and a significant interaction between
AMPH sensitization status × within session period
[F(17,459) ¼ 2.93, P, 0.0001] was found, with Kv10.12/2
AMPH mice more active than Kv10.1
+/+ AMPH during the
last 30 min of the test.
Figure 5. Genotype independent short-term (A and B) and long-term (C and D) effects of AMPH withdrawal on circadian activity and 23 h 4% sucrose solution
consumption (for details, see Materials and Methods). Data are shown as mean + SEM; n ¼ 7-8 per group. ∗P , 0.05 versus Kv10.1+/+, # P, 0.05 versus
non-sensitized group (Veh).
Table 4. Learning and memory
Test/parameter Kv10.1
+/+ Kv10.1
2/2 Kv10.1
+/+AMPH Kv10.1
2/2 AMPH
Y maze spatial novelty
Time in novel arm (%) 54.98+4.76 55.61+4.41 49.53+3.32 54.86+2.67
Entries to novel arm (%) 46.16+9.07 47.46+11.11 42.76+2.51 46.65+1.50
T maze spontaneous alternations
Accuracy after 1 min 0.93+0.06 0.81+0.09 0.93+0.06 0.92+0.07
Accuracy after 15 min 0.81+0.09 0.87+0.08 0.93+0.06 0.92+0.07
Accuracy after 30 min 0.62+0.12 0.56+0.14 0.56+0.11 0.64+0.14
Lack of genotype and AMPH withdrawal effects on learning and memory (for details, see Materials and Methods). Data are shown as mean+SEM; n ¼ 7–8 per
group.
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Sensorimotor gating modified by apomorphine and
haloperidol
There were no significant differences due to genotype
[F(1,27) ¼ 2.34, n.s.] or AMPH sensitization status
[F(1,27) ¼ 1.21, n.s.] in the prepulse inhibition test. There
was a significant genotype-independent difference between
the inhibition induced by different prepulse intensities
[F(2,2157) ¼ 64.05, P, 0.0001] and drugs used
[F(3,2157) ¼ 52.40, P , 0.0001], with haloperidol treatment
reversing the decrease in prepulse inhibition induced by apo-
morphine (Fig. 7A; post hoc tests, P, 0.0001). There was
also a statistically significant interaction between genotype ×
AMPH sensitization status × drug [F(3,2157) ¼ 10.95,
P , 0.0001] with Kv10.1
2/2 AMPH-sensitized mice
showing increased reactivity to apomorphine (post hoc P ,
0.0001) when compared with all other groups (Fig. 7B).
There were no other significant interactions in this test.
Haloperidol-induced catalepsy modified by antidepressants
There was a significant difference between genotypes in the
duration of haloperidol-induced catalepsy [Fig. 8; F(1,27) ¼
5496.73, P , 0.0001] with Kv10.1
2/2 mice showing longer
latency to move. Imipramine and sertraline, but not fluoxetine,
decreased haloperidol-induced catalepsy in both genotypes
[main effect F(3,297) ¼ 385.82, P , 0.0001; post hoc tests
at least P, 0.04]. Statistically significant interactions
between genotype × drug [F(3,297) ¼ 79.30, P , 0.0001]
and genotype × trial [F(2,297) ¼ 398.23, P , 0.0001] were
driven by an increased reactivity to haloperidol in the
Kv10.1
2/2 group. AMPH sensitization had no effect on
haloperidol-induced catalepsy, regardless of genotype
[F(1,27) ¼ 0.04, n.s.].
DISCUSSION
Kv10.1 channels are delayed rectifier potassium channels
widely expressed in the central nervous system (25,26). In
Drosophila, they are involved in regulating excitability of
the neuromuscular junction (36). Because in mammals no
physiological function has been reported so far, we generated
Kv10.1-deficient mice to elucidate the functional role of
Kv10.1 in the brain. Successfully generated Kv10.1-deficient
mice displayed no obvious differences from their littermate
controls in the average life span, reproductive characteristics
or development. Deletion of Kv10.1 did not lead to any
gross anatomical or histological changes in the brain.
Cortex, hippocampus and cerebellum using Nissl neuronal
staining and neuronal markers such as NeuN, calbindin and
calretinin did not show any morphological difference
between both genotypes. Electrical properties of Kv10.1 in
cerebellar PCs of Kv10.1-deficient mice were determined to
elucidate the role of Kv10.1 in controlling firing and excitabil-
ity without interference of Kv10.2 that is not expressed in PCs
(8,25,28), although we had determined that Kv10.2 expression
did not increase in Kv10.1-deficient mice using real time
RT-PCR.
Table 5. Effects in auditory prepulse inhibition test after AMPH treatment
Prepulse inhibition (%) Kv10.1
+/+ Kv10.1
2/2 Kv10.1
+/+AMPH Kv10.1
2/2AMPH
Prepulse intensity 4 months after AMPH withdrawal
4 dB above background (65 dB) 31.60+3.85 19.08+4.66 29.73+4.96 31.81+7.58
8 dB above background 61.24+3.22 39.33+9.03 50.95+4.19 54.92+5.89
12 dB above background 69.97+3.54 58.28+5.13 68.71+3.28 63.86+4.06
16 dB above background 81.04+2.22 56.65+5.53 80.81+1.64 71.58+3.67
Lack of genotype and AMPH withdrawal effects in auditory prepulse inhibition test (for details, see Materials and Methods). Data are shown as mean+SEM;
n ¼ 7–8 per group.
Figure 6. Genotype independent increased activity in AMPH-sensitized mice during AMPH challenge test (1 mg/kg, i.p.) conducted 5 months after sensitization
(for details, see Materials and Methods). Data are shown as mean; n ¼ 7–8 per group.
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We measured a slight increase in input resistance in
Kv10.1
2/2 cells that is, however, not reflected in an earlier
onset of firing or in an increased firing frequency after crossing
the threshold. Kv10.1, thus, could still be involved in setting
the membrane potential in PCs, but its contribution is relative-
ly small. We could not detect any difference between both
genotypes in membrane potential, firing frequency and
action potential shape of cerebellar PCs. We can, therefore,
speculate that the previously strong staining for Kv10.1 in
the PC soma (26) results from a synaptic expression in the
terminals of climbing fibres or basket cells, with only a
minor expression in the PC itself. This actually would be in
line with in situ hybridization data published by Saganich
et al. (25) that showed a strong expression of Kv10.1 mRNA
in the granule layer, but not in the PCs.
Although Kv10.1 is only expressed in the brain, the absence
of Kv10.1 expression in Kv10.1-deficient mice does not cause
any substantial physiological problems, indicating that Kv10.1
function is not crucial for mice life. However, Kv10.1 is essen-
tial for zebrafish development and patterning indicating early
mortality and cell detachment in Kv10.1 knockdown zebrafish
(37). This difference may be attributed to evolutionary differ-
ences, similarly to caveolin-1, the deletion of which is only
lethal in zebrafish, but not in mice (38).
At the behavioural level, Kv10.1
2/2 mice manifest only
hyperactivity both during 60 and 23 h of spontaneous activity
sessions. All other tests applied measuring general health, sen-
sorimotor functioning and gating, anxiety, social behaviour,
learning and memory indicated comparable results in both
genotypes. AMPH sensitization used as a standard procedure
Figure 7. Genotype independent reversal of apomorphine (Apo, 2 mg/kg)-induced decrease in prepulse inhibition by haloperidol (Hal, 0.4 mg/kg) treatment (A,
for details, see Materials and Methods). Observed increased reactivity to apomorphine in Kv10.1
2/2 mice was driven by highly significant increase in reactivity
to Apo in Kv10.1
2/2 AMPH group (B, mean for all prepulse intensities). Data are shown as mean + SEM; n ¼ 5–16 (A) and 7–8 (B) per group. $P , 0.0001
versus Apo, @P , 0.0001 versus all the other groups.
Figure 8. Haloperidol-induced catalepsy. Increased immobility, but normal re-
activity to antidepressants in Kv10.1
2/2 mice in haloperidol-induced catalepsy
test (for details, see Materials and Methods). Data are shown as mean + SEM;
n ¼ 15–16 per group. £P , 0.01 versus Hal, ∗P , 0.0001 versus Kv10.1+/+.
Hal, haloperidol (1 mg/kg); Imi, imipramine (20 mg/kg), Flu, fluoxetine
(20 mg/kg), Sert, sertraline (5 mg/kg). Data from AMPH-sensitized and non-
sensitized animals were pooled due to a lack of differences.
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to induce schizophrenic-like aberrations in rodents (39,40) did
not differentiate between Kv10.1
2/2 and Kv10.1
+/+ animals,
except that Kv10.1
2/2 AMPH-sensitized mice display an
increased reactivity to apomorphine in the prepulse inhibition
test. This might suggest hyperreactivity of the dopaminergic
system in these animals or, consistent with our
haloperidol-induced catalepsy test results, point to a decreased
density/number of dopaminergic receptors.
As reported in previous studies (for review, see 41), AMPH
withdrawal after sensitization procedure induces a depression-
like state in mice lasting several days, characterized by a
significant decrease in locomotor activity and sucrose con-
sumption, but has no impact on anxiety or social behaviour.
Three weeks after AMPH withdrawal, locomotor activity
was significantly higher in AMPH-sensitized animals, but
sucrose consumption returned to the level observed in non-
sensitized animals.
Haloperidol reversed the apomorphine-induced decrease in
prepulse inhibition and, as reported earlier (42), increased
baseline PPI in sensorimotor gating test in all groups of
animals. In contrast to some previous reports (for discussion,
see 43), AMPH withdrawal did not induce decrease in the in-
hibition in our mice. A highly significant increase in respon-
siveness to haloperidol was found in the Kv10.1
2/2 group in
the haloperidol-induced catalepsy test, which has been sug-
gested as an experimental model of parkinsonism (44), irre-
spective of whether or not there had been AMPH
sensitization. Haloperidol blocks dopaminergic receptors, es-
pecially D2 receptors, in the mesocortex and the limbic
system of the brain and is effective in the treatment of acute
psychotic states (45); however, by blocking the dopaminergic
action in the nigrostriatal pathways, haloperidol induces
extrapyramidal-motoric side effects such as dystonias, akathi-
sia and pseudoparkinsonism (46). The hyperresponsivity to
cataleptic effects of haloperidol that we have now observed
in Kv10.1
2/2 mice may suggest a decreased density/number
of somatodendritic D2 receptors in these mice (47,48). It,
therefore, seems possible that a combination of lower doses
of haloperidol and Kv10.1 agonists might prove to decrease
the side effects without reducing the potent antipsychotic ac-
tivity of haloperidol. These interesting findings, combined
with the colocalization of Kv10.1 and tyrosine hydroxylase-
positive dopaminergic neurons in the midbrain (49), suggest
that Kv10.1 may be related to or influence the dopaminergic
system. This possibility merits further study.
Overall, our behavioural tests did not show any signs of
schizophrenic-like aberrations in Kv10.1
2/2 mice and
revealed an almost complete lack of behavioural changes,
except for mildly increased activity. This pattern of outcomes
may prove to have important clinical implications in a rather
different domain. Kv10.1 expression has been shown to be cor-
related with early cancer development of many tumours. In
addition, Kv10.1 favours tumour progression (15). Therefore,
shutting down Kv10.1 function has been proposed as a poten-
tial strategy to treat cancer (50–52). However, this approach
necessitates an evaluation of the consequences induced by
Kv10.1 deletion. The fact that abolition of channel function
does not result in serious cognitive and/or behavioural
effects speaks in favour of the feasibility of cancer treatments
aimed against this newly validated tumour target.
MATERIALS AND METHODS
Generation of Kv10.1
2/2 mice
Targeting vectors were constructed to generate a deletion of
exon 7 that encodes amino acid residues 344–388 of the
Kv10.1 peptide. Genomic regions used in construction of the
targeting vector were cloned from a 129/Sv mouse genomic
library in lfixII (Stratagene). A 7.7 kb BstEII/SalI fragment
from intron 6 was cloned into pBluescript-LoxPneoLoxP
vector as the 5′ arm. A Nhe/Nsi fragment was used to generate
a 2.25 kb 3′arm from intron 7 that was ligated into
pBluescript-Exon-Lox. The mKv10.1 targeting vector was
constructed by the simultaneous ligation of the following
four fragments: a 9.6 kb XhoI/SalI fragment containing the
previously ligated 7.7 kb 5′ arm and the pBluescript-V2-TK
cassette, a 2.2 kb Nhe/Nsi fragment that constitutes the
3′ arm, a 1.6 kb SalI/Nhe fragment containing an Exon 7
and a LoxP site. The resulting 18.4 kb targeting vector was lin-
earized with HindIII and electroporated into 129/SvJ ES cells.
Resistant cells were selected in the presence of G418 and gan-
ciclovir as described previously. A total of 200 clones were
picked, and DNA was isolated (at Genoway). A 0.4 kb frag-
ment generated from the sequence immediately upstream of
the 3′ arm was used to screen ES cell genomic DNA for
correct homologous recombination by Southern Blot
(Fig. 1). One ES cell was positive for homologous recombin-
ation and was injected into C57BL/6 blastocysts that were sub-
sequently transferred into pseudo-pregnant females to generate
chimeric offspring. Chimeras were bred with C57BL/6
females to generate heterozygotes. Germline transmission
was determined by a combination of colour and genotyping.
Adult EllaCre transgenic mice were bred with 8-week-old
Kv10.1
NeoLoxP (F0 crossing) mice. Offspring (F1) were
screened for the presence of EllaCre by PCR. Partial (flox)
or complete (null) Cre recombination patterns were analysed
by PCR. All analyses were carried out on null allele.
Mice were housed in a 12 h light–dark cycle facility with
free access to food and water. Morphological and electro-
physiological experiments were carried out in accordance
with German laws governing the use of laboratory animals.
Behavioural testing was conducted in accordance with the
UK Animals (Scientific Procedures) Act 1986.
Genotyping of mutant mice
Routine genotyping of mice was performed by PCR on DNA
isolated from tail biopsies. Briefly, tail samples were incubated
at 568C (2 h or overnight) in lysis buffer (100 mM Tris pH 8.5,
5 mM EDTA pH 8.0, 200 mM NaCl, 0.2% sodium dodecyl sul-
phate and 0.1 mg/ml proteinase K), followed by isopropanol
precipitation. The DNA was pelleted by centrifugation,
washed with 70% ethanol and resuspended in 100 ml
H2O. For genotyping of Kv10.1
neoloxP knockouts, four
primers were used: (5′F, 5′-TGCGTACATGGTGCTT
GATTTC-3′, NeoR 5′-CGCGAAGGGGCCACCAAAG-3′,
ExF, 5′-CATGATGATTGGCTGTGAGTATG-3′ and 3′R,
5′-CCCTCTTTCCACTAACAGCATC-3′), which resulted in
products of 480 bp for the wild-type gene and 503 bp for the
presence of the neomycin resistance cassette, 534 bp for the
null allele and 580 bp for the flox allele. The four primers
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were used in a multiplex PCR with Biotherm Polymerase
(Genecraft) with the following amplification conditions: at
958C for 4 and 30 cycles at 958C for 30 s, 608C for 30 s,
728C for 50 s and a 7 min incubation at 728C at the end of
the run. Amplification products were resolved on a 1.5%
agarose gel. For genotyping of the presence of EllaCre, two
primers were used (Cre-F, 5′-TCGATGCAACGAGTGA
TGAG-3′ and Cre-R, 5′TTCGGCTATACGTAACAG-3′)
with Biotherm Polymerase (Genecraft) with the following
amplification conditions: at 958C for 4 min, 30 cycles at
958C for 10 s, 558C for 20 s, 728C for 10 s and a 7 min incu-
bation at 728C at the end of the run. For null allele genotyping,
only 5′F, ExF and 3′R Primer were used.
Real time RT-PCR
Mice were sacrificed by CO2 inhalation followed by decapi-
tation. Brains were removed and different brain regions dis-
sected. The tissue was washed in ice cold phosphate-
buffered saline (PBS) and stored in RNAlater buffer
(Applied Biosystems, Foster City, USA) at 2208C. Five
micrograms of total RNA was obtained from brain tissues
using the RNAeasy mini kit (Qiagen, Hilden, Germany), and
first strand cDNA was produced using SuperScript (Invitrogen,
Karlsruhe, Germany) with oligo dT. A housekeeping gene,
Transferrin receptor (TfRc), was used as a control for RNA in-
tegrity and quantification. Real time RT-PCR was performed
in triplicates on 100 ng cDNA using the Light Cycler Detector
(Roche). The following fragments were amplified: 1079–1138
nt from sequence NM_001038607 detected with the mKv10.1a
probe [5′-(FAM)-AACAGGCTGCTGATGCCCTCATCCAC-
(TAMRA)-3′]; 1528–1628 nt from sequence NM_011638
detected with the mTfRc probe [5′-(JOE)-ACTGAGTGGT
TGGAGGGATACCTTTCATCT-(TAMRA)-3′]; 2320–2429
nt from sequence NM_172805 detected with the mKv10.2
probe [5′ (FAM)-GATGGAGAGGACCTTCTCTGTGTCG-
(6-TAMRA)-3′]. Conditions for the PCR reaction were as
follows: 508C for 2 min; 958C for 10 min; 958C for 15 s,
568C for 15 s and 608C for 1 min (40 cycles). The number
of PCR cycles to reach detection threshold was used to deter-
mine specific mRNA content with a standard curve for inter-
polation.
Immunohistochemistry
Mice were anaesthetized with ketamine (75 mg/kg, Medistar,
Holzwickede) and xylazine (15 mg/kg, Riemser, Greifswald)
and subsequently transcardially perfused with PBS pH 7.4
and then with 4% paraformaldehyde (Sigma). Paraffin embed-
ding was done as previously described (26). Brains were seri-
ally cut in the sagittal plane at 5 mm thicknesses with a
microtome (Model RM2255, Leica, Berlin, Germany) and col-
lected on superfrost-coated slides (Thermo Scientific). The
plane of sectioning was oriented to match the drawings of
the mouse brain atlas. Brain morphology was analysed by
using Nissl staining (53). For immunohistochemistry, paraffin
sections were stained with specific markers using Discovery
XT staining module (Ventana Medical Systems, Roche).
Primary antibodies, including NeuN (1:900, Chemicon), Cal-
bindin (1:1000, Millipore) and Carletinin (1:1000, Chemicon)
were incubated for 1 h at 378C, followed by incubation for
32 min at room temperature with biotinylated secondary anti-
bodies (Vector Labs). Immunostaining was developed using
streptavidin-peroxidase and 3,3′-diaminobenzidine and coun-
terstained with haematoxylin. Images were obtained with an
Axioskop microscope (Zeiss, Goettingen, Germany) equipped
with a digital camera (Micropublisher 5.0, QImaging Surrey,
Canada). Linear contrast and brightness corrections were per-
formed using Adobe Photoshop.
Electron microscopy
Kv10.1
+/+ and Kv10.1
2/2 mice, 8 weeks old, were anaesthe-
tized and perfused transcardially with Hank’s balanced salt so-
lution, followed by fixation in 4% paraformaldehyde (Serva,
Heidelberg, Germany) and 0.2% glutaraldehyde (EM grade,
Science Services, Mu¨nchen, Germany) in 0.1 M phosphate
buffer pH 7.3. After dissection, slices of the cerebellar
vermis were postfixed with 2% OsO4 (Science Services,
Munich, Germany) in 0.1 M phosphate buffer pH 7.3 and em-
bedded in EPON (Serva) after dehydration with ethanol and
propylene oxide. Ultrathin sections were prepared with a
Leica Ultracut S ultramicrotome (Leica, Vienna, Austria),
stained with an aqueous solution of 4% uranyl acetate, fol-
lowed by lead citrate (Reynolds, 1963). EM pictures were
taken with a LEO 912 AB electron microscope (Zeiss, Ober-
kochen, Germany) using an on-axis 2k CCD camera (TRS,
Moorenweis, Germany).
Speed congenics
To generate a congenic C57Bl6/N strain, marker-assisted se-
lection of breeders (Elchrom Scientific) was used, and the
progeny containing the highest percentage of C57Bl6/N was
selected for further backcrossing. Seven backcrossings were
needed to obtain 99.9% C57Bl6/N.
Whole-cell current-clamp recordings on cerebellar PCs
Kv10.1
+/+ and Kv10.1
2/2 littermates aged 20–28 days were
decapitated under isoflurane anaesthesia. The cerebellum
was removed and placed in an ice-cold solution containing
(in mM) 60 NaCl, 120 sucrose, 25 NaHCO3, 1.25 NaH2PO4,
2.5 KCl, 25 D-glucose, 0.1 CaCl2, 3 MgCl2, 3 myo-inositol,
2 sodium pyruvate and 0.4 ascorbic acid. Coronal slices of
the cerebellar vermis were cut using a Leica VT1200S
vibratome. The slices were kept at 368C for 1 h in artificial
cerebrospinal fluid containing (in mM) 125 NaCl, 2.5 KCl,
25NaHCO3, 1.25 NaH2PO4, 2 CaCl2, 1 MgCl2, 3 myo-
inositol, 2 sodium pyruvate and 0.4 ascorbic acid that was con-
tinuously bubbled with 95% O2 and 5% CO2. For measure-
ments, slices were transferred to a recording chamber
and constantly perfused with artificial cerebrospinal fluid
at 2–3 ml/min. The bath temperature was maintained at
33+ 18C with an in-line solution heater (Warner instruments).
All recordings were performed in the presence of the GABAA-
receptor antagonist SR95531 [2-(3-carboxypropyl)-3-amino-
6-(4-methoxyphenyl) pyridazinium bromide] and the
AMPA-receptor antagonist NBQX [2,3-dihydroxy-6-
nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione] (Tocris).
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Thick-walled borosilicate pipettes were pulled to resistances
of 3–4 MV and filled with intracellular solution containing
(in mM) 135 K-gluconate, 10 KCl, 10 HEPES, 5 MgATP,
0.5 NaGTP and 0.1 EGTA. Whole-cell current-clamp record-
ings were performed with an EPC 10/2 amplifier controlled by
Patchmaster software (Heka) using difference interference
contrast optics on a Zeiss Axioskop. A calculated liquid junc-
tion potential of 14 mV was subtracted from the recorded vol-
tages. Data were filtered at 10 kHz and sampled at 100 kHz.
Offline analysis was done using Igor Pro software (Wave-
metrics) with custom written macros and the Neuromatic
software package (ThinkRandom). Statistics were performed
with Prism software (GraphPad). Data are presented as
mean+SEM.
Behavioural experiments
For behavioural testing, adult female mice (11–12 weeks at
the beginning of experiments) were used. All animals were
group housed with ad libitum access to water and food
pellets, under a 12 h light/dark cycle, in controlled constant
temperature (21+ 28C) and humidity (60%). All experiments
were conducted during the light phase from 9 a.m. to 5 p.m.
Procedure
The behavioural part of the present study had four stages. The
first stage involved general health screening and basic sensori-
motor test battery, spontaneous locomotor activity and motor
coordination measured by rotarod test. The second phase
started with AMPH sensitization, followed by circadian activ-
ity, sucrose consumption, social interaction and light/dark box
test conducted within 6 days after AMPH withdrawal to
measure the depressive-like state induced by the termination
of AMPH treatment. The third stage started 3 weeks after
AMPH withdrawal and included circadian activity, sucrose
consumption, the elevated plus maze test, hyponeophagia
test, T maze spontaneous alternation and the Y maze test, pre-
pulse inhibition, startle reaction habituation, fear conditioning
and finished with an AMPH challenge test 5 months after
AMPH sensitization. The fourth stage started 3 weeks after
the AMPH challenge test and involved apomorphine-induced
decrease in prepulse inhibition and its reversal by haloperidol
and haloperidol-induced catalepsy and its modification by
antidepressants (imipramine, fluoxetine and sertraline).
General health screening and basic sensorimotor test
battery
Procedures were based on previously published protocols (54)
with some modifications. Single animals were observed in a
transparent plastic cage [17 cm (d) × 27 cm (w) × 20 cm
(h)] for 3 min for any signs of stereotypy, convulsions, exces-
sive activity, tremor, freezing and grooming. Coat condition,
including bald patches and piloerection, missing whiskers
and presence of any physical abnormalities were scored by
direct inspection. Motor abilities and motor reflexes were
scored by: (i) trunk curl: the mouse was held up by its tail,
which elicits a clearly observable forward curling of its
abdomen, (ii) forepaw reaching: forepaw reaching movements
in the mouse held suspended by the tail and slowly moved
towards a metal rod, (iii) inverted screen: the mouse was
placed in the centre of a screen (20.5 cm × 13 cm-wire
mesh, 12 mm2 holes) and the screen was inverted over a 2 s
period with the mouse’s head declining and held steadily
90 cm above a solid, cushioned surface; latency to falling
was noted, with a cutoff time at 60 s and (iv) reactivity to
handling, scored as follows: 1—the mouse struggles when
held by its tail, 2—the mouse struggles when held by the
neck, 3—the mouse struggles when lying supine and 4—no
struggle; test was terminated at any point when struggling
was apparent; pinna reflex and whisker twitch: the mouse
was placed on to a grid and the proximal part of the inner
canthus and the whisker were touched lightly with the tip of
a cotton probe (ear retraction and whisker reaction: absent/
present). Olfaction was measured in a separated 3 min test:
the mouse was placed in a plastic transparent cage [17 cm
(d) × 28 cm (w) × 17 cm (h)] with a drop of diluted (1:100)
almond oil (Langdale, England) on the wall 4 cm from the
floor. Sniffing time, number of sniffs and latency to the first
sniff were scored using the AnyMaze system (Stoelting, USA).
AMPH sensitization
D-amphetamine sulphate (Sigma Chemical Co., St. Louis, MO,
USA) was dissolved in a 0.9% NaCl solution to obtain the
required concentrations. All the solutions were freshly pre-
pared and administered in a volume of 5 ml/kg. Mice were
weighed each day and injected intraperitoneally every 6 h
with increasing doses of AMPH (1–2–3 mg/kg on day 1,
4–5–6 mg/kg on day 2, 7–8–9 mg/kg on day 3 and 10 mg/
kg on day 4 once only). Control animals were given physio-
logical saline injections.
AMPH challenge
Five months after AMPH sensitization, animals were sub-
jected to the AMPH challenge test. The Threshold system
(Version 3, Med Associates) converting change in pressure
on plates into changes in voltage was used. Mice were
placed in cages of 22.5 × 12.5 × 13 cm. The lower detection
threshold was set to 20 V and the upper threshold to 50 V.
The time spent between the two threshold values was taken
to represent locomotor activity in the mice and was collected
in 10 min time bins over three consecutive phases: a 60 min
initial habituation followed by saline injection and 60 min
free exploration, and the third stage, 180 min of free explor-
ation after intraperitoneal injection with 1 mg/kg AMPH.
Locomotor activity
Open field
Spontaneous activity was analysed using automated activity
chambers (27.3 × 27.3 cm) with 3 16 beam I/R arrays
(ENV-510, MED Associates Inc., St. Albans, VT, USA). Hori-
zontal and vertical activity (rearing), mobility and immobility
time, total distance (cm) and velocity (cm/s) were automatic-
ally scored. Data were collected in 5 min intervals over a
60 min test session.
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Circadian activity
The Threshold system (Version 3, Med Associates) converting
changes in pressure on plates into changes in voltage was used
to measure the circadian cycle activity of mice over a 23 h
period (8 a.m. till 7 a.m. the next day). Mice were placed in
cages of 22.5 × 12.5 × 13cm and left with ad libitum food
and water. The time spent above 20 V threshold was taken
to represent locomotor activity in the mice and was collected
in 1 h time bins. The first 3.5 h of data were not included in the
analysis, as this largely represents habituation to the apparatus.
Circadian activity was assessed three times: (i) within 5 days
after AMPH withdrawal and (ii) 3 weeks after AMPH with-
drawal with activity scoring accompanied by 23 h two bottle
free-choice sucrose (4%) preference test and (iii) 5 months
after AMPH withdrawal during AMPH challenge test.
Motor coordination
Accelerating rotarod
Quantitative measurements of motor coordination were per-
formed using an accelerating rotarod (Model 7650, Ugo
Basile, Comerio, VA, Italy) according to the previously pub-
lished protocol (55). Mice were placed on a rod moving at
4 rpm that, after 10 s, began to accelerate at a rate of
20 rpm/min. Mice were given two trials per session and
three sessions per day with a 2 h intersession interval. Mean
speed at fall from two consecutive runs was used as a
measure of motor coordination and motor learning.
Social behaviour
Social approach task: habituation, sociability phase and
preference for social novelty phase
Social approach behaviours were tested in a modified three-
chambered apparatus based on methods previously described
(56). The apparatus was a rectangular, three-chambered box
made of red-tinted Plexiglas (inner compartments size:
20 cm × 30 cm). Manually retractable horizontal doorways
built into the two dividing walls (15 cm high) controlled
access to the side chambers through a 10 cm passage. A top
mounted digital video camera (Ikegami Tsushinki, Japan)
was placed over the boxes to record the session. Stimulus
mice (male CD1) were habituated to the apparatus and to
the wire cage enclosure (8.1 × 8.1 × 21.8 cm), several days
before the start of experiments. The test session began with
a 10 min habituation to all three chambers, during which
lack of innate side preference was confirmed. The subject
was then briefly confined to the centre chamber, whereas the
steel wire cage described above was placed in one of the
side chambers. A novel stimulus CD1 mouse was placed in
an identical wire cage located in the other side of the
chamber. The side containing the novel object and the novel
mouse alternated between the left and right chambers across
subjects. After both stimuli were positioned, the two side
doors were simultaneously removed, and the subject was
allowed access to all three chambers for 10 min. Next, the
mouse was again restricted to the central chamber, and the
empty wire cage replaced by a new one containing a new
stimulus animal. The subject was then allowed access to all
three chambers for 10 min. Time spent in proximity (2 cm)
to the wire cages was recorded and analysed by an
AnyMaze video tracking system (Stoelting, USA). The appar-
atus and wire cages were cleaned with water and 70% alcohol,
respectively, between subjects.
Anxiety
Elevated plus maze
The elevated plus maze test was performed as described by
Lister (57), with some modifications. The plus maze con-
structed from opaque polyvinyl plastic consisted of two open
arms (27 × 5 cm) with a low (0.2 cm) edge and two closed
arms (27 × 5 cm) with 30 cm walls connected to a central
zone (5 × 5 cm) to form a cross, illuminated by a ceiling
lamp (30 lux at the level of the maze). It was elevated to a
height of 50 cm from the floor. The mouse was placed on
the central zone facing one of the open arms. An arm entry
was scored when the mouse placed all four paws into the
arm, and an arm exit when all four paws were removed. The
maze floor was cleaned thoroughly between trials using
water. The time spent in the open arms and number of open
arms entries were recorded for a 5 min period using the
AnyMaze system (Stoelting, USA). Anxiety measures were
calculated using the following formula: percentage of time
spent in the open arm ¼ time spent in the open arms/(the
sum of time spent in both classes of arms) × 100; percentage
of open arm entries ¼ (number of entries in the open arms/
total number of entries) × 100.
Light/dark box
The light/dark box test was performed as previously described
(58). Med Associates activity chambers (ENV-510) were used.
The dark box insert was made of black Perspex designed to
cover half of the area of the activity chamber (27 × 13.9 ×
21.5 cm) with a 4 × 4 cm hole placed in the middle of the
wall at floor level. Time spent in and latency to enter light
and dark zones as well as the number of full-body transitions
between the light (300 lux) and dark (2 lux) compartments
were automatically scored by Med Associates activity software.
The mouse began the experiment in the light compartment.
Hyponeophagia
Hyponeophagia was tested as previously described (59). Sweet
corn kernels were evenly distributed on a white Perspex base
(30 cm2) covered with a translucent plastic jug (approximate
volume 1.5 l, 15 cm diameter) placed upside down. Tests
were conducted under standard laboratory strip lights.
Animals were food deprived overnight. Mice were singly
housed for 20 min prior to testing. The latency to begin to
eat (.2 s uninterrupted consumption) was recorded.
Animals that failed to eat within the 120 s were re-tested
3 min later, for a maximum of three trials, and the sum of
the latencies was noted.
Learning and memory
Spontaneous alternation
The apparatus consisted of a wooden black T maze. Each arm
(30 × 10 × 29 cm) contained a thin layer of unfamiliar female
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bedding. A removable central partition extended 7 cm from
the back of the T into the start arm, dividing the choice area
and allowing access to only one goal arm at a time. A
mouse was placed in the start arm (stem of the ‘T’), facing
away from the goal arms and allowed to freely explore.
After it had entered a goal arm, it was confined there for
30 s by closing a guillotine door, then following a delay of
1, 15 or 30 min, it was returned to the start arm with all
doors raised. If the mouse chose to enter the same arm it
had previously explored, this was recorded as an error. Each
mouse received two trials with each delay over 3 days.
Delays order was counterbalanced within group. The inter-trial
interval was 3 h.
Y maze spatial novelty
This task was based on a previously published protocol (60). A
Perspex Y maze with arms of 30 × 8 × 20 cm was placed into
a room containing a variety of extra-maze cues. A thin layer of
wood chips covered the floor. This was not changed between
mice, but was redistributed between phases for individual
mice and between mice to eliminate meaningful intramaze
cues. Mice were assigned two arms (a start arm and one
other arm) to which they were exposed during the first trial,
the exposure phase, for 5 min. This selection of arms was
counterbalanced with respect to genotype. An entry/exit into/
from an arm was defined by a mouse placing all four paws
inside/outside an arm. The test phase began 1 min after the ex-
posure phase, during which the mouse had been put into a
holding cage. During the test phase, mice were allowed free
access to all three arms. Mice were placed at the end of the
start arm and allowed to explore all three arms for 2 min.
The time that mice spent in each arm was recorded and ana-
lysed by AnyMaze system (Stoelting, USA). Novelty prefer-
ence was calculated as time in novel arm × 100 (time in all
three arms).
Fear conditioning
Fear-conditioning experiments were carried out by a
computer-controlled fear-conditioning system (TSE-Systems,
Bad Homburg, Germany) as previously described (61).
During training, mice initially explored the context for
180 s. Thereafter, a single paired (delay) presentation occurred
with a 30 s tone (5 kHz, pulsed 5 Hz and 70 dB SPL) followed
at tone offset by a 1 s shock (unconditioned stimulus: US;
0.5 mA, constant current). The US was delivered through the
stainless steel floor grid (4 mm, distance 9 mm) in the fear-
conditioning box. Mice were returned to their home cages
30 s after US offset. Acquisition occurred in a transparent
Plexiglas cage [36 cm (w) × 21 cm (d) × 20 cm (h)] placed
within a fear-conditioning box that was made of white
acrylic plastic, under a broadband auditory background noise
(white noise, 50 dB SPL) and constant light (80 lux). The fear-
conditioning cage was thoroughly cleaned with 70% ethanol
before each experiment.
Context-dependent memory was tested 24 h after acquisi-
tion by re-exposure to the conditioning box for 180 s
without any phasic stimulation such as tone and shock. The
tone-dependent (cued) memory test was performed 24 h after
the contextual memory test in a novel context. The novel
context was a rectangular black Plexiglas box [36 cm (w) ×
21 cm (d) × 20 cm (h)] with plain white frozen floor installed
within TSE-activity photo beam system. The light intensity
was reduced to 6 lux, and strawberry smell (Dale Air Ltd,
UK) was introduced to render the novel context different
from the conditioning context. Initially, behaviour was moni-
tored for 180 s without tone presentation (pre-CS phase)
before the tone was replayed for 180 s (CS phase). The last
minute of the pre-CS phase and the first minute of the CS
phase were used for assessment of cued-conditioned
responses. Freezing time was calculated by the fear-
conditioning system to determine shock and cued responses.
The threshold for freezing was set at 2 s.
Prepulse inhibition of acoustic startle
Prepulse inhibition
Two months later, startle response and prepulse inhibition of
acoustic startle responses were measured by the SR-Lab
System (San Diego Instruments, San Diego, CA, USA). A
test session began by placing a mouse in the Plexiglas cylin-
der, where it was left undisturbed for 5 min. A test session
consisted of 10 trial types: a 40 ms, 120 dB sound burst
used as the startle stimulus, 4 different acoustic 20 ms pre-
pulse stimuli: 69, 73, 77, 81 dB (4, 8, 12 and 16 dB above
the background noise) and 4 combinations of prepulses and
startle stimuli spaced by 100 ms delay, starting with the
onset of the prepulse stimulus. Finally, there were trials in
which a 65 dB stimulus (identical to the background noise)
was presented to measure baseline movement in the cylin-
ders. Six blocks of the 10 trial types were presented in
pseudorandom order such that each trial type was presented
once within a block of 10 trials. The session started and fin-
ished with five startle stimuli. The average inter-trial interval
was 15 s (ranged from 10 to 20 s). The average startle amp-
litude was recorded every 1 ms during the 65 ms sampling
window starting at the onset of the startle stimulus in
pulse-alone and prepulse-plus-pulse trials, and at the onset
of the prepulse stimulus, the prepulse-alone trials were
used to determine the stimulus reactivity. The following
formula was used to calculate percentage of prepulse inhib-
ition of a startle response: 100–(prepulse-plus-pulse × 100/
pulse-alone).
Prepulse inhibition modified by apomorphine
and haloperidol
Two months later, startle response and prepulse inhibition of
acoustic startle response after apomorphine, haloperidol,
apomorphine + haloperidol or vehicle (0.09% saline) were
measured in a Latin square design using stimuli identical
to the described above. Each animal was exposed to each
solution once every 2 days. All drug solutions were freshly
prepared on the day of testing and were administered in a
volume of 10 ml/kg. Apomorphine HCl (Apo, Sigma Chemi-
cals, St. Louis, USA) was dissolved by sonication in sterile
0.9% NaCl solution to obtain the required concentration of
2.0 mg/kg. Haloperidol (Hal, Janssen-Cilag, Baar, Switzer-
land) was prepared from solvent ampoules (5 mg/ml) diluted
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with sterile 0.9% NaCl solution to obtain the required concen-
tration of 0.4 mg/kg. The first injection (Hal or saline solution)
was made 60 min before testing via the intraperitoneal route.
The second injection, either Apo or saline solution, was
administered 15 min before testing via the subcutaneous
route. The doses and pretreatment times were based on
those commonly employed in studies of a similar nature in
mice (62). The first five startle-alone trials were excluded.
The reactivity scores obtained on prepulse-plus-pulse trials
and pulse-alone trials were converted into percentage score
denoting the percentage of inhibition of startle response at
each prepulse intensity by the formulae: 100–(prepulse-
plus-pulse × 100/pulse-alone).
Haloperidol-induced catalepsy modified by antidepressants
Catalepsy was measured by the bar test. Mice were positioned
so that their hindpaws were on the bench and their forelimbs
rested on a 1 cm diameter horizontal metal bar, 4 cm above
the bench. The length of time the mice maintained this pos-
ition was recorded to a maximum of 600 s. Measurements
were conducted 60, 120 and 180 min after haloperidol admin-
istration (1 mg/kg, intraperitoneally). The following drugs
were administered intraperitoneally 30 min before haloperi-
dol: imipramine (20 mg/kg), fluoxetine (20 mg/kg), sertraline
(5 m g/kg) or saline (0.09%). Each animal was exposed to
all drug solutions (Hal + Imi, Hal + Flu, Hal + Ser and
Hal + Veh) every second day according to a Latin Square
design.
Behavioural data analysis
Data were analysed using one- or two-factor analysis of vari-
ance (ANOVA), followed by Bonferroni-modified least sig-
nificant difference tests. When animals were tested several
times in the same task or when within-session periods were
used, ANOVAs with repeated measures were applied. All
tests of significance were performed at a ¼ 0.05 using
Unistat 5.6 (Unistat Ltd, London, UK).
SUPPLEMENTARY MATERIAL
Supplementary material is available at HMG online.
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